BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32283024)

  • 1. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
    Zhao Z; Bourne PE
    J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
    Goyal S; Jamal S; Shanker A; Grover A
    J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
    Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
    J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
    Singhi EK; Horn L
    Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.
    Petrazzuolo A; Perez-Lanzon M; Martins I; Liu P; Kepp O; Minard-Colin V; Maiuri MC; Kroemer G
    Cell Death Dis; 2021 Jul; 12(8):713. PubMed ID: 34272360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
    Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
    J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.
    Yu Z; Zhao R
    Anticancer Drugs; 2018 Jul; 29(6):513-519. PubMed ID: 29570100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of
    Fukuda K; Takeuchi S; Arai S; Katayama R; Nanjo S; Tanimoto A; Nishiyama A; Nakagawa T; Taniguchi H; Suzuki T; Yamada T; Nishihara H; Ninomiya H; Ishikawa Y; Baba S; Takeuchi K; Horiike A; Yanagitani N; Nishio M; Yano S
    Cancer Res; 2019 Apr; 79(7):1658-1670. PubMed ID: 30737231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
    Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
    Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
    Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
    BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations.
    He MY; Li WK; Meiler J; Zheng QC; Zhang HX
    Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role and targeting of anaplastic lymphoma kinase in cancer.
    Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
    Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
    Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
    Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.